However, in some cases, CLN10-associated Batten disease represents a potentially targetable neurodegenerative disorder with a juvenile-onset [58, 59], that is similar to the CLN7-type Batten disease, for which the AON therapy Milasen has been reported to show clinical benefits in a single patient [3]. Here, CTSD is linked to juvenile neuronal ceroid lipofuscinosis.